retatrutide patent eli lilly Lilly's tirzepatide showed positive results in late-stage trial as treatment for heart failure Eli Lilly infiltrates anti-obesity market

Reach out to our dedicated clinical team today to review your treatment plan

Adults with #obesity who received the highest dose of a once-weekly injection of #retatrutide lost an average of 24.2% of their body #weight at 48 weeks compared with placebo, data from a phase 2 study show

It is fundamental to research-grade methodology

Despite the fact that they're often referred to as "natural" alternatives to GLP-1 agonist medications, Metzgar says it's important to differentiate between the two

Many of these women have already implemented nutritional changes as well as regular exercise, and their GLP-1 medication has allowed them to achieve the results that these initial changes could not

References Batterham, R